Longeveron Inc.
Clinical-stage biotech developing cell therapies for aging and life-threatening conditions.
LGVN | US
Overview
Corporate Details
- ISIN(s):
- US54303L2034
- LEI:
- Country:
- United States of America
- Address:
- 1951 NW 7TH AVENUE, 33136 MIAMI
- Website:
- https://www.longeveron.com/
- Sector:
- Manufacturing
Description
Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product, laromestrocel (Lomecel-B™), is a cell-based therapy designed to repair, regenerate, and restore damaged tissue. Longeveron's clinical development is focused on several key indications, including Hypoplastic Left Heart Syndrome (HLHS), a rare congenital heart defect in infants for which it has an orphan drug designation. Other primary clinical programs target Alzheimer's disease and Aging Frailty. For its Alzheimer's program, the U.S. FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company's research aims to improve healthspan by addressing unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Longeveron Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Longeveron Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Longeveron Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
